Bicycle Therapeutics plc (NASDAQ:BCYC) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $46.86.

A number of equities analysts recently commented on BCYC shares. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price on shares of Bicycle Therapeutics in a research report on Wednesday, April 10th. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research report on Friday, May 3rd.

Bicycle Therapeutics Price Performance

Shares of NASDAQ:BCYC opened at $20.24 on Monday. The stock has a market cap of $865.87 million, a PE ratio of -4.55 and a beta of 0.88. The company’s fifty day moving average is $22.46 and its 200 day moving average is $21.50. Bicycle Therapeutics has a 52 week low of $12.54 and a 52 week high of $27.50. The company has a quick ratio of 10.42, a current ratio of 10.42 and a debt-to-equity ratio of 0.09.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.63. The company had revenue of $19.53 million for the quarter, compared to analysts’ expectations of $6.06 million. Bicycle Therapeutics had a negative net margin of 404.14% and a negative return on equity of 49.35%. The business’s revenue was up 298.9% on a year-over-year basis. Research analysts anticipate that Bicycle Therapeutics will post -4.44 earnings per share for the current year.

Insider Activity

In other news, CEO Kevin Lee sold 3,158 shares of Bicycle Therapeutics stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $23.81, for a total transaction of $75,191.98. Following the sale, the chief executive officer now owns 387,270 shares of the company’s stock, valued at approximately $9,220,898.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 5,312 shares of company stock valued at $126,139. Corporate insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds have recently bought and sold shares of the business. Woodstock Corp boosted its stake in Bicycle Therapeutics by 4.5% during the fourth quarter. Woodstock Corp now owns 21,479 shares of the company’s stock worth $388,000 after acquiring an additional 926 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Bicycle Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,727 shares of the company’s stock worth $122,000 after acquiring an additional 1,706 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Bicycle Therapeutics by 71.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,859 shares of the company’s stock worth $171,000 after acquiring an additional 2,858 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in Bicycle Therapeutics by 3.9% during the fourth quarter. Handelsbanken Fonder AB now owns 139,800 shares of the company’s stock worth $2,528,000 after acquiring an additional 5,300 shares in the last quarter. Finally, PNC Financial Services Group Inc. bought a new position in shares of Bicycle Therapeutics in the fourth quarter worth approximately $137,000. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.